Clinical Trials
58 trialsBevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
ThINKK-01
St. Justine's Hospital
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
City of Hope Medical Center
A Study of LY3039478 in Participants With Advanced Cancer
Eli Lilly and Company
ON-5001
OncoNano Medicine, Inc.
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
PROBE
Antengene Corporation
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
BPGbio
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
Synlogic
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers
Innovent Biologics (Suzhou) Co. Ltd.
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
Memorial Sloan Kettering Cancer Center
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Celgene
CD205SHUTTLE
Menarini Group
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
IACS-010759 in Advanced Cancers
M.D. Anderson Cancer Center
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
A Study of LY2835219 in Japanese Participants With Advanced Cancer
Eli Lilly and Company
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas
Chinese PLA General Hospital
A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients
Eli Lilly and Company
α-TEA in Advanced Cancer
Providence Health & Services
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
Incyte Corporation
CDDO to Treat Solid Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Melphalan With BBBD in Treating Patients With Brain Malignancies
OHSU Knight Cancer Institute
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Verastem, Inc.
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
Cornerstone Pharmaceuticals
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
H. Lee Moffitt Cancer Center and Research Institute
Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Mirati Therapeutics Inc.
EMD 521873 in Advanced Solid Tumors, MTD Finding
Merck KGaA, Darmstadt, Germany
Rapamycin With Grapefruit Juice for Advanced Malignancies
University of Chicago
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Altor BioScience
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)